格隆汇2月5日丨国际医学(000516.SZ)在互动平台表示，公司控股股东及一致行动人质押的股票不涉及 转融通业务。 ...

公司公告汇总 西安国际医学投资股份有限公司预计2025年度归属于上市公司股东的净利润亏损29,500万元至31,500万 元，较上年同期亏损25,412.85万元同比扩大。扣除非经常性损益后的净利润预计亏损32,000万元至 35,000万元。营业收入预计为406,000万元至408,000万元，较上年同期481,546.68万元下降。公司称受市 场波动、DRG支付政策改革等因素影响，营业收入同比下降，虽实施降本增效措施使第四季度亏损收 窄，但收入规模尚未覆盖运营成本和期间费用。本次业绩预告未经注册会计师审计。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 业绩披露要点：国际医学预计2025年归属净利润亏损2.95亿元至3.15亿元。 公司公告汇总：国际医学2025年度营收预计为40.6亿元至40.8亿元，同比下滑。 截至2026年1月30日收盘，国际医学（000516）报收于4.89元，较上周的5.21元下跌6.14%。本周，国际 医学1月26日盘中最高价报5.26元。1月30日盘中最低价报4.84元。国际医学当前最新总市值10 ...

Core Insights - The report provides an analysis of the hair medical industry in China, highlighting key players, market share, and competitive dynamics. Group 1: Industry Overview - The main listed companies in the hair medical industry include Yonghe Medical, Xianju Pharmaceutical, ST Meigu, Yisheng Pharmaceutical, Zhendong Pharmaceutical, International Medical, Kanghui Pharmaceutical, Kangyuan Pharmaceutical, Kang Enbei, and Furuida [1]. - The competitive landscape shows that companies with registered capital exceeding 1.5 billion yuan are in the leading position, while those with capital between 500 million to 1.5 billion yuan are in the first tier, and companies with less than 500 million yuan are in the second tier [1]. Group 2: Regional Distribution - Representative enterprises in the hair medical industry are mainly distributed across provinces such as Shaanxi, Zhejiang, Jilin, Liaoning, Shandong, and Jiangsu, with a notable concentration in Shaanxi and Zhejiang [4]. Group 3: Market Dynamics - As of November 21, 2025, leading hair transplant chains like Yonghe Hair Transplant, Dama Micro-needle (Kefa Source), and Bilian Sheng have over 30 stores each [7]. - The market for Minoxidil, a common hair growth medication, is highly concentrated, with the top three brands holding over 97% market share in online pharmacies as of 2024 [10][14]. Group 4: Competitive Analysis - The hair transplant sector has many institutions with low concentration, leading to intense competition, while the market for Minoxidil is dominated by a few key players [12][16]. - The threat of new entrants is moderate due to certain industry barriers, while substitutes like wigs and hair tattoos pose a threat due to their lower cost and quicker application [16].

截至2026年1月29日收盘，国际医学(000516)报收于5.01元，上涨0.4%，换手率2.3%，成交量50.67万 手，成交额2.53亿元。 董秘最新回复 投资者： 现在人人脱发白发等很多，还有很多人有睡眠等问题，公司是否有这方面的专科呢。 董秘： 您好，感谢您对公司的关注。公司旗下医疗机构通过中医科、皮肤科和医学美容中心，协同解 决患者脱发、白发问题。中医科以整体调理为核心，通过中药内服、针灸、中药外洗等方式进行个性化 辨证治疗。皮肤科设立了毛发专病门诊，配备毛发镜、激光生发仪等专业设备，能够对患者头皮和毛囊 健康状况进行可视化评估，结合中药调理、现代药物及激光生发等中西医结合方式，制定针对性治疗方 案。医学美容中心可开展植发等毛发修复项目，满足不同患者的改善需求。公司旗下医疗机构还设有中 医科、临床心理科、睡眠医学科、睡眠呼吸障碍诊疗中心及神经内科视频脑电监测室等多个科室，通过 多学科协同诊疗方式解决睡眠相关健康问题。中医科运用中药、针灸、穴位贴敷、拔罐、推拿、安神香 囊等多种手段进行综合调理。临床心理科及睡眠医学科配备多导睡眠监测、经颅磁刺激仪、失眠治疗仪 等专业设备，结合药物治疗、物理治疗、心理 ...

Core Viewpoint - The company is actively developing a specialized and international healthcare service system to meet the growing demand for medical tourism and high-quality medical care from both domestic and international patients [1] Group 1: Company Initiatives - The company has established an international diagnosis and treatment department and special outpatient services within its medical institutions [1] - Multilingual service support and professional translation equipment have been implemented to assist patients [1] - The company collaborates with multiple insurance companies to enable direct insurance payments for patients [1] Group 2: Service Optimization - The company leverages its JCI certification experience to continuously optimize service processes in alignment with international standards [1] - The company is actively promoting pilot applications for international medical services to provide high-quality healthcare services to both domestic and international patients, as well as to sub-healthy populations [1]

证券日报网讯 1月29日，国际医学在互动平台回答投资者提问时表示，为应对日益增长的高品质就医需 求，近年来，公司充分利用自身资源平台，积极对接海外合作伙伴，发挥综合性国际化医院的优势，为 海内外患者、亚健康人群提供优质的医疗健康服务。公司2024年门急诊服务量达257.27万人次，2025年 门急诊服务量保持增长，具体信息请留意公司后续披露的定期报告。目前，公司旗下医疗机构外籍患者 门急诊服务量占比小，但呈逐年上升趋势。 （文章来源：证券日报） ...

Group 1 - The company International Medicine (000516) has sold its shares in Beijing Hanshi United Biotechnology Co., Ltd. [1] - Currently, there is no equity relationship between International Medicine and Beijing Hanshi United Biotechnology Co., Ltd. [1]

Core Viewpoint - The company is leveraging its resources to enhance international collaboration and provide quality healthcare services to both domestic and overseas patients, with a focus on increasing the proportion of foreign patients in its medical institutions [1] Group 1 - The company has been actively engaging with overseas partners to utilize its comprehensive international hospital advantages [1] - The service volume for foreign patients in the company's medical institutions is currently small but shows a year-on-year increasing trend [1]

Core Viewpoint - International Medical (000516.SZ) emphasizes the importance of traditional Chinese medicine and the concept of "food as medicine," actively exploring innovative health products and services in its hospitals [1] Group 1: Product Development - The hospital's nutrition department has not yet launched homemade yogurt products but is focusing on developing traditional Chinese health products [1] - Products developed include weight loss tea, spleen health tea, liver health tea, constipation tea, throat-soothing tea bags, and blood health tea, which have become popular choices for patient daily health management [1] Group 2: Service Offering - The nutrition department collaborates with the hospital's restaurant to offer a service that combines traditional dietary therapy with modern nutrition, including stews, snacks, noodles, and soybean milk [1] - This service features customized recipes, standardized production, and dedicated delivery, providing dietary options with health benefits for inpatients and those in need [1]

Core Viewpoint - The company is leveraging its resource platform to connect with overseas partners and enhance its international hospital services, aiming to provide high-quality healthcare services to both domestic and international patients, particularly those in sub-health conditions [1] Group 1 - The company has been actively engaging with overseas partners to maximize its resources [1] - The company is focusing on providing quality healthcare services to both domestic and international patients [1] - The proportion of foreign patients in the company's medical institutions is currently small but is showing a year-on-year increase [1]